Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Japan deploys the military to counter a surge in bear attacks - 2From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- 37 Delightful Ferris Wheels, Do You Like Them?
- 4Intriguing Social Unesco World Legacy Locales All over The Planet
- 5The Conclusive Manual for Spending plan Travel: Opening Undertakings on a Tight budget
- Portable Installment Answers for Independent ventures
- Israel and Lebanon's Hezbollah continue to trade attacks
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- Meet the Artemis crew in NASA's first astronaut mission to the moon in more than a half-century
- From Loner to Force to be reckoned with: Individual Accounts of Change
- Don't fall for it: These common tourist scams in Rome are easy to avoid if you know what you're looking for
- European Travel Objections for 2024
- Bayer sues COVID vaccine makers over mRNA technology
- Watch SpaceX launch NASA's Pandora exoplanet-studying satellite on Jan. 11
